person · Reporting owner
Breedlove Robert Charles
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Principal Accounting Officer | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phathom Pharmaceuticals, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,465 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Tax withholding · Disposed 460 · Balance 59,465 F1: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 8,191.78 |
Reported balance
Holding disclosure · report date 2026-09-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,191.78 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 8, 2026 20:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 460 | $9.05 | $4,163.00 |
DisclosureSEC source: 0001193125-26-385250 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,465 F1 · kind: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 20:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 1,555 | $11.04 | $17,159.43 |
DisclosureSEC source: 0001193125-26-306165 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,925 F1 · kind: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:11 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 414 | $12.56 | $5,199.84 |
DisclosureSEC source: 0001193125-26-088730 · ownership.xml · nonDerivative · entry 4 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,480 F4 · kind: Represents shares underlying RSUs that were surrendered by the reporting person to the Issuer upon vesting of such RSU in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:11 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 964 | $12.56 | $12,107.84 |
DisclosureSEC source: 0001193125-26-088730 · ownership.xml · nonDerivative · entry 3 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,894 F3 · kind: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:11 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 2,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088730 · ownership.xml · nonDerivative · entry 2 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,858 F2 · shares: Represents shares issued upon vesting of performance stock units granted to the reporting person on February 27, 2025 based on the achievement of performance criteria determined to be satisfied on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:11 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088730 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,068 F1 · shares: Represents restricted stock units ("RSUs") granted on February 27, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:42 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 776 | $13.61 | $10,561.36 |
DisclosureSEC source: 0001193125-26-021164 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,068 F1 · kind: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 22:50 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Tax withholdingCommon Stock | 230 | $16.28 | $3,744.40 |
DisclosureSEC source: 0001193125-25-327135 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,844 F1 · kind: Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:30 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 524 | $13.51 | $7,079.24 |
DisclosureSEC source: 0001193125-25-267057 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,407 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 20:40 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 461 | $12.09 | $5,573.49 |
DisclosureSEC source: 0000950170-25-113822 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,931 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,692 | $8.36 | $14,151.72 |
DisclosureSEC source: 0000950170-25-096917 · ownership.xml · nonDerivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,392 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in mutliple transactions at prices $8.364 and $8.35. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2025 Filed May 21, 2025 21:17 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000950170-25-075870 · ownership.xml · derivative · entry 1 Breedlove Robert Charles · CIK 0002066645 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on May 19, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.